MA29250B1 - Cyclohexylamides servant d'antagonistes des recepteurs de dopamine d3, d2 et de 5ht1a - Google Patents

Cyclohexylamides servant d'antagonistes des recepteurs de dopamine d3, d2 et de 5ht1a

Info

Publication number
MA29250B1
MA29250B1 MA30137A MA30137A MA29250B1 MA 29250 B1 MA29250 B1 MA 29250B1 MA 30137 A MA30137 A MA 30137A MA 30137 A MA30137 A MA 30137A MA 29250 B1 MA29250 B1 MA 29250B1
Authority
MA
Morocco
Prior art keywords
dopamine
formula
heteroaryl
cycloalkyl
alkenyl
Prior art date
Application number
MA30137A
Other languages
English (en)
Inventor
Csongor Eva Againe
Gyoergy Domany
Janos Galambos
Istvan Gyertyan
Bela Kiss
Katalin Saghy
Eva Schmidt
Original Assignee
Richter Gedeon Vegyeszet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Vegyeszet filed Critical Richter Gedeon Vegyeszet
Publication of MA29250B1 publication Critical patent/MA29250B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES LIGANDS SELON LA FORMULE (I) PRÉFÉRANT UN SOUS-TYPE DE RÉCEPTEUR DE LA DOPAMINE D3 ET D2 ET DE LA SÉROTONINE 5-HT1A ; DANS LADITE FORMULE, A CORRESPOND À UN ALKYLE, ALKÉNYLE, ARYLE, HÉTÉROARYLE, CYCLOALKYLE OU À UN GROUPE DE LA FORMULE -NR1R2, OÙ R1 ET R2 REPRÉSENTENT INDÉPENDAMMENT UN SUBSTITUANT CHOISI PARMI UN HYDROGÈNE, UN ALKYLE, UN ALKÉNYLE, UN ARYLE, UN HÉTÉROARYLE OU UN CYCLOALKYLE OU BIEN R1 ET R2 FORMENT UN ANNEAU HÉTÉROCYCLIQUE AVEC L'ATOME D'AZOTE VOISIN ET EN OPTION AVEC AUSSI UN OU PLUSIEURS HÉTÉROATOMES ; M EST UN NOMBRE ENTIER DE 0 À 1 ; N EST UN NOMBRE ENTIER DE 1 À 2, ET/OU DES ISOMÈRES GÉOMÉTRIQUES ET/OU DES STÉRÉOISOMÈRES ET/OU DES DIASTÉRÉOMÈRES ET/OU DES SELS ET/OU DES HYDRATES ET/OU DES SOLVATES DE CEUX-CI. L'INVENTION CONCERNE AUSSI DES PROCESSUS POUR LES PRODUIRE, DES COMPOSITIONS PHARMACOLOGIQUES LES CONTENANT ET LEUR UTILISATION DANS LE TRAITEMENT ET/OU LA PRÉVENTION D'UN ÉTAT QUI NÉCESSITE LA MODULATION DES RÉCEPTEURS DE LA DOPAMINE ET/OU DE 5-HT1A.
MA30137A 2005-02-03 2007-08-13 Cyclohexylamides servant d'antagonistes des recepteurs de dopamine d3, d2 et de 5ht1a MA29250B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU0500170A HUP0500170A3 (en) 2005-02-03 2005-02-03 Piperazine derivatives, process for producing them and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
MA29250B1 true MA29250B1 (fr) 2008-02-01

Family

ID=89985795

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30137A MA29250B1 (fr) 2005-02-03 2007-08-13 Cyclohexylamides servant d'antagonistes des recepteurs de dopamine d3, d2 et de 5ht1a

Country Status (19)

Country Link
US (1) US7705003B2 (fr)
EP (1) EP1844030A1 (fr)
JP (1) JP2008528674A (fr)
KR (1) KR20070101265A (fr)
CN (1) CN101107236A (fr)
AU (1) AU2006211002A1 (fr)
BR (1) BRPI0606895A2 (fr)
CA (1) CA2594845A1 (fr)
EA (1) EA200701640A1 (fr)
HU (1) HUP0500170A3 (fr)
IL (1) IL183740A0 (fr)
MA (1) MA29250B1 (fr)
MX (1) MX2007009353A (fr)
MY (1) MY139750A (fr)
NO (1) NO20074447L (fr)
TN (1) TNSN07255A1 (fr)
TW (1) TWI311990B (fr)
WO (1) WO2006082456A1 (fr)
ZA (1) ZA200705839B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1870405A1 (fr) * 2006-06-22 2007-12-26 Bioprojet (Aza)cyclohexanes carbonylées comme ligands du récepteur D3 de la dopamine
HU230748B1 (hu) * 2007-05-11 2018-02-28 Richter Gedeon Nyrt Új piperazin só és előállítási eljárása
HUP0700353A2 (en) 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
US20090036468A1 (en) * 2007-08-03 2009-02-05 Forest Laboratories Holdings Limited Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands
US7875610B2 (en) 2007-12-03 2011-01-25 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
RS53866B1 (sr) 2008-07-16 2015-08-31 Richter Gedeon Nyrt. Farmaceutske formulacije koje sadrže ligande dopaminskih receptora
HU230067B1 (hu) 2008-12-17 2015-06-29 Richter Gedeon Nyrt Új piperazin só és eljárás előállítására
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
HUP0800766A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Vegyeszet Process for the preparation of piperazine derivatives
US8586579B2 (en) * 2010-06-21 2013-11-19 Hoffmann-La Roche Inc. Anellated pyridine compounds
US8470828B2 (en) 2010-07-06 2013-06-25 Hoffmann-La Roche Inc. Anellated pyridine compounds
US8877778B2 (en) 2010-12-15 2014-11-04 Hoffmann-La Roche Inc. Benzofurane compounds
US8722683B2 (en) * 2011-02-17 2014-05-13 Hoffmann La-Roche Inc. Benzodioxole piperazine compounds
US8921397B2 (en) 2011-05-04 2014-12-30 Hoffmann-La Roche Inc. Benzofurane-piperidine compounds
US9376396B2 (en) 2012-10-22 2016-06-28 AbbVie Deutschland GmbH & Co. KG Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor
UY35420A (es) 2013-03-15 2014-10-31 Abbvie Inc Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
AR095264A1 (es) 2013-03-15 2015-09-30 Abbvie Deutschland Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
CN104140421B (zh) * 2013-05-08 2017-04-05 上海医药工业研究院 苯并异噻唑类化合物及在制备抗精神分裂症药物中的应用
CN106518841B (zh) 2015-09-15 2019-03-05 浙江京新药业股份有限公司 环己烷衍生物或其立体异构体或盐及其制备与应用
WO2017045599A1 (fr) * 2015-09-15 2017-03-23 浙江京新药业股份有限公司 Dérivé de cyclohexane ou stéréoisomère ou sel de ce dernier, préparation et utilisation de ce dernier
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
WO2018021447A1 (fr) 2016-07-28 2018-02-01 塩野義製薬株式会社 Composé cyclique condensé contenant de l'azote ayant un effet antagoniste du récepteur de la dopamine d3
JP7017797B2 (ja) * 2017-02-24 2022-02-09 深▲チェン▼市霊蘭生物医薬科技有限公司 新規なドーパミンｄ３受容体選択的リガンド及びびその調製方法並びに医薬使用
CA3089498A1 (fr) 2018-01-26 2019-08-01 Shionogi & Co., Ltd. Composes cycliques condenses ayant un effet antagoniste du recepteur d3 de la dopamine
US11447484B2 (en) 2018-01-26 2022-09-20 Shionogi & Co., Ltd. Cyclic compound having dopamine D3 receptor antagonistic effect
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
US12459931B2 (en) 2019-11-05 2025-11-04 Shanghai Hansoh Biomedical Co., Ltd. Benzothiophene derivative regulator, preparation method therefor and use thereof
CN114634479B (zh) * 2020-12-16 2025-02-07 北京盈科瑞创新药物研究有限公司 一种派嗪衍生物、其制备方法及应用
EP4594294A1 (fr) * 2022-09-30 2025-08-06 The United States of America, as represented by the Secretary, Department of Health and Human Services Agonistes partiels du récepteur d3/d2 de la dopamine destinés au traitement de troubles neuropsychiatriques
CN119874636A (zh) * 2025-01-16 2025-04-25 鲁南制药集团股份有限公司 一种卡利拉嗪的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763609A (en) 1996-03-21 1998-06-09 Neurogen Corporation Certain pyrrolo pyridine-3-carboxamides; a new class of gaba brain receptor ligands
US5703083A (en) 1996-04-15 1997-12-30 Neurogen Corporation N-aminoalkyl-1-biphenylenyl-2-carboxamides; new dopamine receptor subtype specific ligands
US5703237A (en) 1996-04-18 1997-12-30 Neurogen Corporation N-Aminoalkyl-2-anthraquinonecarboxamides; new dopamine receptor subtype specific ligands
JPH10152470A (ja) 1996-09-25 1998-06-09 Yoshitomi Pharmaceut Ind Ltd ピペラジン化合物
KR100372926B1 (ko) * 1998-06-02 2003-02-25 마쯔시다덴기산교 가부시키가이샤 고분자전해질형연료전지 및 그 제조방법
SE9802208D0 (sv) 1998-06-22 1998-06-22 Astra Pharma Inc Novel compounds
JP4156859B2 (ja) 2001-06-20 2008-09-24 コスモ石油株式会社 軽油の水素化処理触媒及びその製造方法並びに軽油の水素化処理方法
HUP0103987A3 (en) 2001-09-28 2004-11-29 Richter Gedeon Vegyeszet Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
HU227543B1 (en) 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
IL183740A0 (en) 2007-09-20
ZA200705839B (en) 2009-05-27
TNSN07255A1 (en) 2008-12-31
BRPI0606895A2 (pt) 2009-07-21
CN101107236A (zh) 2008-01-16
MY139750A (en) 2009-10-30
US7705003B2 (en) 2010-04-27
HUP0500170A2 (en) 2006-11-28
HU0500170D0 (en) 2005-04-28
AU2006211002A1 (en) 2006-08-10
KR20070101265A (ko) 2007-10-16
HUP0500170A3 (en) 2007-11-28
MX2007009353A (es) 2007-09-21
TW200639158A (en) 2006-11-16
CA2594845A1 (fr) 2006-08-10
US20080103140A1 (en) 2008-05-01
WO2006082456A1 (fr) 2006-08-10
EP1844030A1 (fr) 2007-10-17
NO20074447L (no) 2007-10-18
TWI311990B (en) 2009-07-11
JP2008528674A (ja) 2008-07-31
EA200701640A1 (ru) 2008-02-28

Similar Documents

Publication Publication Date Title
MA29250B1 (fr) Cyclohexylamides servant d'antagonistes des recepteurs de dopamine d3, d2 et de 5ht1a
MA28024A1 (fr) Derives de (thio) carbamoyl-cyclohexane utilises en tant qu'antagonistes des recepteurs d3/d2
MA30456B1 (fr) Nouveau dérivé de coumarine présentant une activité anti-tumorale.
PE20040164A1 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas
PE20070321A1 (es) Compuestos heterociclicos como inhibidores de proteasas
MA30355B1 (fr) Derives d'azabicyclo [3. 1. 0] hexyle utilises comme modulateurs des recepteurs de la dopamine d3
TN2009000204A1 (fr) Spirocetones servant d'inhibiteurs d'acetyl-coa-carboxylase
MA29460B1 (fr) Derive polycyclique de la carbamoylpyridone a activite inhibitrice sur l'integrase du vih
TW200716528A (en) Cyclopropanecarboxamide derivatives
DE602004026629D1 (de) Cyclopropanderivate und ihre pharmazeutische verwendung
CO6321130A2 (es) Piridinas carboxamidas como inhibidores de la 11 beta-hsd1
MA31373B1 (fr) Composes amino-heterocycliques
MXPA05010824A (es) Compuestos biciclicos como antagonistas del receptor nr2b.
MY140528A (en) Spiroketal derivatives and their use as therapeutic agents for diabetes
TW200745058A (en) MMP-13 selective inhibitors
TW200719886A (en) Dihydrobenzofuran derivatives and uses thereof
WO2009057784A1 (fr) Composé hétérocyclique
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
TNSN07357A1 (en) Indanyl-piperazine derivatives, method for preparing same and pharmaceutical compositions containing same
TN2015000237A1 (fr) Modulateurs de recepteurs d'androgenes selectifs nouveaux
TW200616679A (en) Modified-release preparation
MA30326B1 (fr) Agent pour la prevention/le traitement du syndrome du colon irritable
TH144950A (th) อนุพันธ์ 7(ไธโอ)-คาร์บามออิล-ไซโคลเฮกเซนที่เป็นแอนทากอนิสท์ของตัวรับโดแพมีน d3/d2
TH65446A (th) อนุพันธ์ 4-ไพริมิโดนซึ่งถูกแทนที่ที่ตำแหน่ง 3
TH82581B (th) สารสำหรับป้องกันหรือรักษาโรคเส้นประสาท